TICKERNERD
Menu
TLSATLSAHealthcare · Biotechnology

TLSA Stock Forecast: Tiziana Life Sciences Ltd. (Bermuda) Price Predictions for 2026-2027

Last close, 3 Aug 2026
$0.97
−5.89% on the day

The 1 Wall Street analysts covering Tiziana Life Sciences Ltd. (Bermuda) hold a median 12-month price target of $8.99 — +827.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$123.4M
Ticker Nerd rank
20 / 100
Median analyst target
$8.99
Analysts covering
1
Total return, dividends reinvested
1W
+6.5%
1M
−26.0%
YTD
−34.9%
1Y
−59.3%
From 52W high
−60.6%
From 52W low
+8.9%
$0.89
$2.46
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TLSA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tiziana Life Sciences Ltd. (Bermuda) on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
20 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
72
Volatility
71
Accruals
71
Value
46
Revisions
31
Issuance
23
Growth
22
Momentum
20
Quality
9

Size (72): Smaller than most of the companies we track.

Quality (9): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

The rank is the raw material. Whether the rules would actually own Tiziana Life Sciences Ltd. (Bermuda) — and when they’d sell — is the membership.

Wall Street

TLSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TLSA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26TLSAHigh $8.99Median $8.99Low $8.99

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $8.99Median $8.99High $8.99

The green dot is the last close — the median target sits +827.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 Sept 2022ThinkEquityInitiatesBuy—
13 June 2022ThinkEquityInitiatesBuy—
12 Apr 2021Zacks Investment ResearchInitiatesNot Rated—
21 Sept 2020HC Wainwright & Co.MaintainsBuy$25 → $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

TLSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Tiziana Life Sciences Ltd. (Bermuda) (TLSA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.0×

Cheaper than 90% of US stocks

Price / sales
—
Price / book
12.6×

Cheaper than 8% of US stocks

EV / EBITDA
−5.7×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−924.3%

Higher than 1% of US stocks

Return on assets
−116.0%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TLSA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TLSATiziana Life Sciences Ltd. (Bermuda)$123.4M
20
NRXPNRX Pharmaceuticals, Inc.$132.1M
20
HURATuHURA Biosciences, Inc.$131.8M
15
GNLXGenelux Corp.$131.5M
25
UNCYUnicycive Therapeutics, Inc.$133.8M
25
VTVTvTv Therapeutics, Inc.$127.4M
87
CNTBConnect Biopharma Holdings Ltd.$127.2M
13
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TLSA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest TLSA news & analysis

Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition

Benzinga · 31 July 2026positive

Tiziana Life Sciences announced quantitative PET imaging results from the third patient in its Phase 2 clinical trial, indicating a reduction in neuroinflammation for a rare neurodegenerative condition.

Why it matters — A TLSA watcher would care because these imaging results represent progress in the company's clinical development for a rare neurodegenerative disease.

Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient

Proactive Investors · 31 July 2026positive

Tiziana Life Sciences reported imaging results from the third multiple system atrophy (MSA) patient to complete dosing in its Phase 2 trial of intranasal foralumab, with PET scans showing reductions in brain inflammation in regions commonly affected by MSA.

Why it matters — This is the third MSA patient to show reduced brain inflammation on treatment, suggesting a potential pattern of clinical benefit that could support the therapeutic promise of intranasal foralumab for this neurodegenerative disease.

Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

GlobeNewsWire · 31 July 2026positive

Tiziana Life Sciences announced quantitative PET imaging results from the third Multiple System Atrophy patient in its Phase 2 clinical trial, showing a reduction in brain inflammation after treatment with intranasal foralumab.

Why it matters — The continued positive imaging results from a third patient strengthen the case that intranasal foralumab may reduce neuroinflammation in MSA, a key milestone for the drug's clinical development.

FAQ

Frequently asked questions about TLSA stock

What is the TLSA stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Tiziana Life Sciences Ltd. (Bermuda) have a median 12-month price target of $8.99, with estimates ranging from $8.99 to $8.99. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TLSA stock a buy right now?

Of the 1 analysts covering Tiziana Life Sciences Ltd. (Bermuda), 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tiziana Life Sciences Ltd. (Bermuda) 20 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TLSA?

As at 1 Aug 2026, Tiziana Life Sciences Ltd. (Bermuda) ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (72 of 100).

Will TLSA stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +827.2% from the last close, and Ticker Nerd's factor model ranks Tiziana Life Sciences Ltd. (Bermuda) 20 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TLSA stock forecast for 2030?

No analyst covering Tiziana Life Sciences Ltd. (Bermuda) publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TLSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8.99 to $8.99 over the next 12 months.

How has TLSA stock performed over the past year?

Tiziana Life Sciences Ltd. (Bermuda) returned -59.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tiziana Life Sciences Ltd. (Bermuda) do?

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing transformative therapies for neurodegenerative and neuroinflammatory diseases.

What is the latest news on TLSA?

The most recent item we track (Benzinga, 31 July 2026): "Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition". Tiziana Life Sciences announced quantitative PET imaging results from the third patient in its Phase 2 clinical trial, indicating a reduction in neuroinflammation for a rare neurodegenerative condition.

Company

About Tiziana Life Sciences Ltd. (Bermuda).

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Headquartered in London and founded in 2013, the company specializes in alternative routes of immunotherapy using innovative drug delivery technologies, particularly intranasal administration. Its lead asset is intranasal foralumab, a fully human anti-CD3 monoclonal antibody designed to modulate the immune system for conditions such as non-active secondary progressive multiple sclerosis, Alzheimer’s disease, amyotrophic lateral sclerosis, and other central nervous system disorders. Tiziana Life Sciences emphasizes non-intravenous delivery methods, aiming to improve safety, tolerability, and patient convenience through nasal, oral, and inhaled formulations. The company operates within the broader healthcare and biotechnology sector, contributing to the development of novel immunomodulatory therapies that target complex inflammatory pathways in the brain and other tissues. Its activities center on clinical development, immune system modulation, and advanced drug delivery platforms for serious unmet medical needs.

CEO Dr. Ivor R. Elrifi Ph.D. · 10 employees · United Kingdom · https://www.tizianalifesciences.com